Shanghai Junshi Biosciences rises on EC's approval for marketing Toripalimab

Shanghai Junshi Biosciences

25/09/2024 04:39

** Shares of Shanghai Junshi Biosciences Co Ltd  1877.HK 
surge 10.1% to HK$12.26, their highest since Aug. 23, on course
for the second consecutive session of gain
    ** Stock on track for the biggest one-day pct rise since
April 9; sixth biggest pct gainer in healthcare index  .HSCIH ,
which rises 2.3%
    ** Company says European Commission has approved for
marketing of toripalimab for treatment of metastatic
nasopharyngeal carcinoma, or a malignant tumor in epithelium of
the nasopharynx which is common types of head and neck cancers 
    ** Says the approval is applicable to all 27 member states
of the European Union, Iceland, Norway and Liechtenstein
    ** Shanghai-listed stock  688180.SS  rises 4% to 25.39 yuan,
highest since Sept. 13
    ** Hang Seng Commerce & Industry Index  .HSNC  adds 1.4% and
Hang Seng Index  .HSI  rises 1.6%
    ** Hong Kong stock dropped 42.7% YTD, Shanghai shares down 
41.6% YTD

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))